ImmunoGen, a Waltham-based biotechnology company, has made significant advances in developing antibody-drug conjugates (ADCs) for cancer patients. Its portfolio includes mirvetuximab soravtansine, an ADC that targets the folate-receptor alpha (FRa) to treat platinum-resistant ovarian cancer. It also includes Pivekimab sunirine, a CD123-targeting ADC currently in Phase II clinical trial for the treatment of acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. The company's preclinical programs include IMGC936, a co-development with MacroGenics, Inc., and anti-FRa product candidate IMGN151. ImmunoGen has established collaborations with major players in the healthcare industry, including Roche, Amgen/Oxford BioTherapeutics, and Bayer HealthCare AG. The company has bullish prospects for the use of its innovative technology to develop cancer treatments.